Titan Biotech Limited (524717) Fair Value & Analysis
Other · IN · Market cap ₹1.5B
Fair value as of: Jul 4, 2026
From 26 valuation models · updated today
Share price −13.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹80.18 – ₹529.20 · fair‑value band ₹326.12 – ₹997.10 · the ₹389.10 price screens below the ₹567.91 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Titan Biotech Limited (524717) currently trades at ₹389.10, while our model-based Fair Value estimate is ₹567.91 — implying the stock looks roughly 46.0% undervalued today. We read business quality at 69/100 (solid quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Titan Biotech Limited generated revenue of ₹1.1B at a net margin of 21.3%. Revenue grew 76.5% year over year. It earns a return on equity of 49.5%. Net debt stands at ₹21.9M. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Titan Biotech Limited manufactures and sells biological products in India. The company offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as specter whey protein, collagen peptides, brown rice protein, fish collagen, pea protein isolate, chicken protein isolate, soya protein isolate, milk protein, and protein hydrolysate; and nutraceutical and pharmaceutical products comprising sodium caseinate, chondroitin sulfate, hyaluronic acid, methyl sulphonyl methane, chelated minerals, peptone, OX bile extract, cholic acid, cerebroprotein hydrolysate, methyl sulphonyl methane, iron protein succinylate, medicinal yeast, and brewer yeast protein, as well as liver, meat, malt, and yeast extracts. In addition, it provides products in the areas of animal nutrition, including binding agents, chelates minerals, mold inhibitors, proteins, and yeasts. The …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Titan Biotech Limited reported revenue of ₹2.1B in FY2026 versus ₹1.2B in FY2022, a compound +13.7%/yr. Reported net income was ₹299M in FY2026, compounding +8.3%/yr from FY2022.
Is 524717 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Titan Biotech Limited (524717) undervalued?
What is the fair value of 524717?
What is the quality score of 524717?
What is the revenue of Titan Biotech Limited (524717)?
What is the net profit margin of 524717?
Does Titan Biotech Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.